Brought to you by 
Arrowhead buys another RNAi business, this time from Novartis, for $35mm
20 Sep 2017
Executive Summary
For the second time, Arrowhead Research Corp. is taking on unwanted RNAi assets from Big Pharma; in this case, Novartis AG divested its RNAi R&D pipeline and related assets. Novartis, which will assign Arrowhead patents and patent applications, announced in April 2014 that it was significantly cutting internal drug discovery activities in the RNAi field.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arrowhead buys another RNAi business, this time from Novartis, for $35mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice